Literature DB >> 34168871

Ossifying fibromyxoid tumor of soft tissue: A case report with review of literature.

Ahlem Bchir1, Ahlem Bellalah1, Nouha Ben Abdeljelil1, Manel Njima1, Leila Njim1, Abdelfateh Zakhama1, Rym Hadhri1.   

Abstract

INTRODUCTION AND IMPORTANCE: The ossifying fibromyxoid tumor of soft tissue is a rare tumor of intermediate differentiation and uncertain lineage that occurs in adults mostly in the extremities and the trunk. PRESENTATION OF CASE: we present a case of 57 year-old man presenting with a right scapular mass. It was a subcutaneous and painless mass that was largely excised. The diagnosis of ossifying fibromyxoid tumor of the right shoulder was made. The follow up of 1 year was without recurrence and metastasis. CLINICAL DISCUSSION: The ossifying fibromyxoid tumor of soft tissue is exceptional, microscopic diagnosis and management is challenging, considering the scarcity of the tumor.
CONCLUSION: More cases and retrospective studies are needed to understand the pathogenesis and to determine optimal treatment regimens.
© 2021 The Authors.

Entities:  

Keywords:  Case report; EMA, Epithelial Membrane Antigen; EMNST, epithelioid malignant nerve sheath tumors; GFAP, Glial fibrillary acidic protein; Intermediate differentiation; OFT, ossifying fibromyxoid tumor; Ossifying fibromyxoid tumor; Pathology; SEF, sclerosing epithelioid fibrosarcoma; SMA, Smooth Muscle Actin; Soft tissue

Year:  2021        PMID: 34168871      PMCID: PMC8209675          DOI: 10.1016/j.amsu.2021.102479

Source DB:  PubMed          Journal:  Ann Med Surg (Lond)        ISSN: 2049-0801


Introduction

The ossifying fibromyxoid tumor of soft tissue (OFT) is a rare mesenchymal neoplasm of intermediate differentiation and uncertain lineage [1]. It was firstly described in 1989 by Enzinger [[1], [2], [3]]. Approximately 300 cases have been reported in the literature until now [1]. It occurs in any soft tissue location, mostly in the extremities and the trunk [2,4]. We report a new case of OFT arising in the right shoulder with a review of literature in order to highlight its clinical, histopathological, and prognostic aspects. We had follow the instruction of 2020 scare guidelines [5].

Presentation of case

A 57-year-old man, with no familiar or personal or psychosocial history, presented with a right scapular slow-growing tumor. The physical examination revealed a subcutaneous painless mass measuring 10 cm in diameter. The patient had not drug allergy. He agreed to have an excision of the mass. An orthopedist, with a 15-years experience, underwent the operation without any complications. The patient left the hospital after one week. The macroscopic examination showed an encapsulated, multinodular firm and tan-white tumor containing calcifications. Histologically, the tumor was composed of uniform, round or spindle shaped cells arranged in nests and cords and deposited in a variably myxoid and collagenous stroma with an incomplete ring of lamellar bone at the periphery of the tumor (Fig. 1). Tumor cells had pale nuclei and small amounts of eosinophilic cytoplasm (Fig. 2). Mitoses were absents. On immunohistochemical study, the tumor cells were diffusely positive for S-100 protein (Fig. 3) as well as vimentin and focally positive for desmin. Immunostaining with pancytokeratin, EMA, SMA was negative. The diagnosis of OFT of the right shoulder was made. After 1 year of follow up, the patient is in total remission without recurrence or distant metastasis.
Fig. 1

The tumor is surrounded by a thick capsule and contains an incomplete shell of lamellar bone at the periphery. Tumor cells are arranged in nests and cords in a variably myxoid and collagenous stroma (HE x 40).

Fig. 2

The tumor is composed of uniform round, or spindle cells with a pale nuclei and a small amounts of eosinophilic cytoplasm (HE x 400).

Fig. 3

Diffuse positivity for S100 protein.

The tumor is surrounded by a thick capsule and contains an incomplete shell of lamellar bone at the periphery. Tumor cells are arranged in nests and cords in a variably myxoid and collagenous stroma (HE x 40). The tumor is composed of uniform round, or spindle cells with a pale nuclei and a small amounts of eosinophilic cytoplasm (HE x 400). Diffuse positivity for S100 protein.

Discussion

The ossifying fibromyxoid tumor of the soft tissue (OFT) is extremely rare. It was firstly described in 1989 by Enzinger in a series of 59 cases from the Armed Forces Institute of Pathology (AFIP) [1,2,6]. Its pathogenesis is still unclear [7]. Rearrangement of the PHF1, locus at the chromosome 6p21 had recently been observed in 80% of OFT [1,3]. Graham had also reported a deletion of the SMARCB1/INI1, locus at the chromosome 22p12.1 in 71% of cases [1,7,8]. The OFT is a mesenchymal tumor of an uncertain differentiation. Cartilaginous, smooth muscle and nerve sheath origin was suggested but this theory needs to be proven [1,3,6,7]. This tumor arises mostly in adults with male predominance and mean age of 50 years [1,2,6]. It occurs usually in the extremities [1,6]. Less common sites include the trunk, the head and the neck, the oral cavity, the retroperitoneum and the mediastinum [1,3,6,7]. It is an indolent, well-defined, slow growing and firm mass located in the subcutaneous tissue [9]. Location in skeletal muscle or in tendon is rarely seen [9]. Most of tumors range from 3 to 5 cm [9]. The radiographic examination shows a well-defined mass with an in complete ring of peripheral ossification [1,7]. In 60–70% of the case, the Computer Tomography reveals the peripheral “bone shell” [1,7]. The macroscopic finding shows frequently a well-circumscribed, multinodular mass, covered by a thick fibrous pseudocapsule with a tan-white color and a firm to rubbery consistency [[1], [2], [3],7]. Folpe and Weiss described three subtypes of OFT typical, atypical and malignant. This classification is based on cellularity, nuclear atypia, and mitotic index [1,7,9]. The typical subtype is composed of trabeculae and nest of uniform round to spindle shaped cells surrounded by a fibromyxoid stroma [1,2,6,7,9]. Mitotic rate is usually 1 to 2 per 50 high power-fields [2]. At the periphery of this lesion, incomplete ring of lamellar and metaplastic bone is found in 70% of cases [9]. Satellite nodules have sometimes been observed. The malignant form is characterized by high mitotic activity (>2 mitosis per 50 high power-fields) and high cellularity [3]. The atypical form is described as a tumor that doesn't fulfill all criteria of malignant or typical subtype [1,4,6]. Immunohistochemically, the tumor cells are positive for S100 protein and vimentin in 60–70% of cases and for desmin in 13% of cases [1,4]. The atypical and malignant forms express less S100 protein [1,4]. Rarely, the tumor can show positivity for CD10, keratin and GFAP [6]. The loss of expression of INI1 has recently been reported with mosaic patterns [1,3]. Cytogenetic analysis using FISH had identified PHF1 arrangement in about 80% of OFT with fusion to EP400 in 44% of cases [1,8] or TFE3 arrangement [8]. In addition, Antonescu et al. had discovered a number of new fusion including ZC3H7B-BCOR, MEAF6-PHF1, EPC-PHF1,CREBBP-BCORL1 and KDM2A-WWTR1 ([10]). The main histologic differential diagnoses include epitheloid schwannoma, epithelioid malignant nerve sheath tumors, mixed tumor/myoepithelioma of soft tissue, low grade fibromyxoid sarcoma, extraskeletal osteosarcoma and sclerosing epithelioid fibrosarcoma [1,3,6]. The typical subtype of OFT is characterized by a low risk of local recurrence with a rate of 0–12% and no distant metastasis [1,3,4,6]. However, the atypical form has an intermediate malignancy with a local aggressivity and recurrence [[1], [2], [3], [4],6]. The malignant form is considered as a sarcoma due to its aggressive behavior and its high risk of recurrence and metastasis with a rate of 20–60% [1,11,12]. The common metastatic sites are lung and soft tissue [1,4,6,12]. The local recurrence rate is respectively 0–13% and 0–60% for atypical and malignant OFT [12]. The treatment is based on the wide excision of the tumor [1,7].

Conclusion

Ossifying fibromyxoid tumor of soft tissue is a rare mesenchymal tumor of intermediate differentiation and uncertain lineage. Follow up is needed especially for atypical and malignant subtypes. More cases and retrospective studies are required to understand the pathogenesis of this disease and to determine optimal treatment regimens.

Ethical approval

This study is exempt from ethical approval at our institution.

Sources of funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author's contribution

Ahlem Bchir: Drafting, conception, analysis. Ahlem Bellalah: conception, collecting data. Nouha Ben Abdeljelil, Manel Njima: acquisition and interpretation of data. Rym Hadhri, Leila Njim, Abdelfateh Zakhama: revising.

Research Registration number

Name of the registry: N/A* Unique identifying number or registration ID:N/A* Hyperlink to your specific registration (must be publicly accessible and will be checked).

Guarantor

Ahlem Bellalah

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Availability of data and material

The authors declare that there are that all data and materials are available.

Declaration of competing interest

The authors have no conflict of interest to disclose.
  10 in total

Review 1.  Ossifying Fibromyxoid Tumor: A Review With Emphasis on Recent Molecular Advances and Differential Diagnosis.

Authors:  Cody S Carter; Rajiv M Patel
Journal:  Arch Pathol Lab Med       Date:  2019-12       Impact factor: 5.534

2.  The SCARE 2020 Guideline: Updating Consensus Surgical CAse REport (SCARE) Guidelines.

Authors:  Riaz A Agha; Thomas Franchi; Catrin Sohrabi; Ginimol Mathew; Ahmed Kerwan
Journal:  Int J Surg       Date:  2020-11-09       Impact factor: 6.071

3.  Ossifying fibromyxoid tumor: a study of 6 cases of atypical and malignant variants.

Authors:  Kossivi Dantey; Karen Schoedel; Oleksandr Yergiyev; Richard McGough; Alka Palekar; Uma N M Rao
Journal:  Hum Pathol       Date:  2016-11-02       Impact factor: 3.466

4.  Ossifying fibromyxoid tumor of soft parts. A clinicopathological analysis of 59 cases.

Authors:  F M Enzinger; S W Weiss; C Y Liang
Journal:  Am J Surg Pathol       Date:  1989-10       Impact factor: 6.394

5.  Ossifying fibromyxoid tumour: a rare soft tissue tumour of intermediate malignancy.

Authors:  F Binesh; A Akhavan; H Navabii
Journal:  BMJ Case Rep       Date:  2011-03-24

6.  Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma.

Authors:  Cristina R Antonescu; Yun-Shao Sung; Chun-Liang Chen; Lei Zhang; Hsiao-Wei Chen; Samuel Singer; Narasimhan P Agaram; Andrea Sboner; Christopher D Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2013-11-28       Impact factor: 5.006

Review 7.  Ossifying Fibromyxoid Tumor: An Update.

Authors:  David Bakiratharajan; Bharat Rekhi
Journal:  Arch Pathol Lab Med       Date:  2016-04       Impact factor: 5.534

8.  Cutaneous malignant ossifying fibromyxoid tumor.

Authors:  Thomas L Cibull; Steven D Billings
Journal:  Am J Dermatopathol       Date:  2007-04       Impact factor: 1.533

9.  A rare case report of a typical variant ossifying fibromyxoid tumor (OFMT), located in the retroauricular perimastoid region.

Authors:  Theodoros Varakliotis; Gianluca Bellocchi; Alberto Eibenstein; Gilberto Acquaviva; Francesco Casorati
Journal:  Int J Surg Case Rep       Date:  2018-02-14

Review 10.  Ossifying Fibromyxoid tumor of soft parts in head and neck: case report and literature review.

Authors:  Ignacio A Velasco; Ran Zhang; Tiejun Li; Diancan Wang
Journal:  Diagn Pathol       Date:  2018-03-27       Impact factor: 2.644

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.